Skip to main content
Pharmaceutical Services

Part 2: Polymer-Drug Conjugates

Introduction:
Nanotechnology in the Pharmaceutical Industry

Part 2 of 4: Polymer-Drug Conjugates

Although the FDA has not adopted a formal regulatory definition of “nanotechnology” or “nanoparticles,” these terms are generally used for engineered materials with at least one dimension in the range of roughly 1–100 nanometers. In other words, simply having particles between 1 and 100 nm in your formulation does not, by itself, make it “nanotechnology”—the particles must be deliberately engineered, rather than present only as incidental nanoscale material.

Part 2: Polymer-Drug Conjugates – Design Principles, Clinical Examples, and Drug Delivery Applications

In drug formulation development, many otherwise promising APIs struggle with poor solubility, rapid clearance, off-target toxicity, or limited tissue targeting. Polymer-drug conjugates address these barriers by covalently attaching drugs to polymers, offering the potential to tune pharmacokinetics, solubility, and targeting through chemical modification rather than completely redesigning the API itself. Besides the drug delivery benefits, polymer-drug conjugates can generate life-cycle management opportunities for well-established and/ or approved APIs.

This is Part 2 of our 4-part series, where we focus on polymer-drug conjugate design, specific use cases, and emerging technology in the field.

What Are Polymer-Drug Conjugates?

Polymer-drug conjugates are single molecular entities in which a polymeric backbone (e.g., PEG, poly(amino acids), natural polymers) is covalently linked to a drug (small molecule, peptide, protein, antibody, or nucleic acid). Often this is accomplished with a cleavable linker designed to release the drug in the right tissue or intracellular compartment triggered by environmental or enzymatic pathways.

By modifying the polymer, linker moiety, and conjugation site, drug formulators can tweak circulation time, distribution, and release properties without changing the intrinsic pharmacology of the API.

Common Types of Polymer-Drug Conjugates

1. Polymer–Small Molecule Conjugates

Polymer–small molecule conjugates are single entities in which a low–molecular weight drug is covalently linked to a polymer backbone, typically via a defined, often cleavable linker.

Examples of Polymers:

  • Poly(ethylene glycol) (PEG)
  • Polysaccharides (e.g., dextran and hyaluronic acid)
  • Poly(amino acids) (e.g., poly(glutamic acid), poly(sarcosine))

Pros:

  • Improve aqueous solubility of hydrophobic APIs, typically small molecules
  • Increase hydrodynamic size to reduce renal clearance
  • Enable better target tissue distribution (e.g., exploitation of the Enhanced Permeability and Retention (EPR) effect in tumors)

Drug Product Example:

MOVANTIK® (naloxegol): PEG-conjugated (PEGylated) naloxol that limits blood–brain barrier penetration, allowing treatment of opioid-induced constipation with minimal impact on centrally mediated analgesia at recommended doses.

2. Protein–Polymer Conjugates

Protein–polymer conjugates are single macromolecular entities in which therapeutic proteins are covalently linked to polymers such as PEG or PSA, often at defined amino acid residues on the protein surface.

Examples of Polymers

  • Poly(ethylene glycol) (PEG)
  • Polysialic acid (PSA)
  • Polysaccharides (e.g., dextran and hyaluronic acid)

Pros:

  • Extend circulation half-life by reducing renal clearance
  • Provide steric bulk and shielding against proteolytic enzymes and immune recognition
  • Reduce dosing frequency and lessen PK variability

Drug Product Example:

  • NEULASTA® (pegfilgrastim): PEGylated granulocyte colony-stimulating factor (G-CSF) with a substantially longer half-life than filgrastim, enabling less frequent injections.

3. Peptide–Polymer/ Peptide–Lipid Conjugates

Peptide–polymer and peptide–lipid conjugates are defined molecular constructs in which therapeutic peptides are covalently linked to hydrophilic polymers and/or lipophilic chains, often via short linker moieties.

Polymer Examples:

  • Poly(ethylene glycol) (PEG)
  • C14–C18 fatty acids (e.g., myristic, palmitic, and stearic)
  • Polysialic acid (PSA)

Pros:

  • Protect peptides from enzymatic degradation
  • Improve stability and/ or solubility
  • Enhance membrane interaction and tissue distribution

Drug Product Example:

  • ZILBRYSQ® (zilucoplan): a macrocyclic peptide complement C5 inhibitor bearing a C16 lipid attached via a short monodisperse PEG linker, which provides a PK profile compatible with once-daily subcutaneous dosing for generalized myasthenia gravis.

4. Antibody–Drug Conjugates (ADCs)

Antibody–drug conjugates (ADCs) are targeted bioconjugates composed of an antibody-based targeting moiety, a cytotoxic payload, and a covalent linker that can be cleaved by specific mechanisms or triggers.

Linker Examples:

  • Protease-cleavable peptide linkers (e.g., Val–Cit, Val–Ala)
  • Acid-labile hydrazone linkers
  • Reducible disulfide linkers

Pros:

  • Combine antibody specificity with potent cytotoxic payloads
  • Improve tumor selectivity
  • Reduce systemic toxicity versus free cytotoxins
  • Linker design can tune payload release profile

Drug Product Example:

  • Trodelvy® (sacituzumab govitecan-hziy): An ADC comprising:
    • Anti-Trop-2 monoclonal antibody
    • The payload is SN-38, the active metabolite of irinotecan and a topoisomerase I inhibitor.

A short PEG-containing, hydrolytically labile linker (CL2A) that releases SN-38 after ADC internalization and supports a bystander effect in the tumor microenvironment.

5. Nucleic Acid–Polymer Conjugates

Nucleic acid–polymer conjugates are macromolecular entities in which oligonucleotides or aptamers are covalently attached to polymer backbones, typically at defined terminal or internal positions on the nucleic acid.

Polymer Examples:

  • Poly(ethylene glycol) (PEG)
  • HPMA – poly(N-(2-hydroxypropyl)methacrylamide) copolymers
  • Poly(amino acids) (e.g., poly(sarcosine))

Pros:

  • Increase resistance to nuclease-mediated degradation
  • Extend circulation half-life and enable less frequent dosing
  • Potential for tissue-specific delivery via receptor–ligand interactions

Drug Product Example:

  • Pegaptanib sodium (Macugen®): a 28-nucleotide RNA aptamer covalently linked to a 40 kDa PEG chain. PEGylation improves stability and extends intravitreal half-life, enabling treatment of neovascular age-related macular degeneration.

Key Advantages of Polymer-Drug Conjugates

  • Improved solubility for poorly water-soluble APIs
  • Extended circulation half-life and reduced dosing frequency
  • Targeted delivery via size, EPR effect, or ligand-based targeting
  • Controlled release through pH-, enzyme-, hydrolysis-, or redox-sensitive linkers
  • Reduced off-target toxicity by controlling where and when the drug is released
  • New IP opportunities around linker chemistry, polymer architecture, and conjugation strategy

Formulation Design Considerations & Challenges

  • Polymer selection:
    • Biocompatibility and biodegradability (PEG vs poly(amino acids) vs other polymers or lipids)
    • Regulatory precedent and burden
    • Potential immunogenicity (e.g., growing concern with anti-PEG antibodies)
  • Linker selection:
    • Cleavable vs non-cleavable linkers
    • Cleavage trigger mechanism (pH, enzymes, redox, hydrolysis)
    • Balancing circulating stability and on-target release
  • Drug loading / stoichiometry:
    • Degree of substitution or drug-to-antibody ratio (DAR)
    • Effect on potency, PK, aggregation, stability, and manufacturability
  • Analytical considerations:
    • Development of relatively complex LC-MS, SEC, CE methods
    • Need for stability-indicating methods to characterize conjugation and degradation
  • Manufacturing and sterility:
    • Scalable conjugation processes
    • Impurity profile
    • Robust sterility assurance for injectable products

Emerging Technology Spotlight: Nucleic Acid–Polymer Conjugates

Nucleic acid–polymer conjugates are an emerging class of therapeutics in which RNA or DNA molecules are covalently linked to polymers and/or targeting ligands for the same reasons other APIs are conjugated: to improve stability, extend circulation time, and enable tissue-specific delivery. The inherent fragility of nucleic acids—especially RNA makes this approach particularly attractive. By covalently attaching polymers, formulators aim to reduce nuclease-mediated degradation, slow rapid clearance from circulation, and improve cellular uptake. The attachment of ligands offers potential tissue-specific targeting (e.g., liver cells) for these APIs.

Silence Therapeutics is a key player in this field through the development of their mRNAi GOLD™ platform. Their siRNA drug candidate Zerlasiran (SLN360) is a GalNAc-conjugated siRNA targeting the mRNA responsible for producing apolipoprotein(a) in the liver. The GalNAc–siRNA conjugate is designed for uptake into hepatocytes via the asialoglycoprotein receptor (ASGPR), enabling targeted reduction of lipoprotein(a) levels in patients at high risk for cardiovascular disease.

The inherent challenges with nucleic acid delivery—instability, rapid clearance, and the need for efficient, tissue-specific uptake—make it likely that nucleic acid–polymer conjugates will become an increasingly important part of a drug formulators toolkit.